New Asthma Drug Effective in Trials

Thursday, 13 Mar 2014 12:03 PM


  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink

GlaxoSmithKline Plc said its non-inhaled treatment for a type of severe asthma met the main goals in two late-stage studies.
In one study, the treatment, mepolizumab, showed statistically significant reduction in the frequency of exacerbations in patients of severe eosinophilic asthma compared with a placebo, GSK said on Wednesday.
The second study showed that patients on mepolizumab achieved greater reduction in their oral corticosteroid dose compared with those on placebo, while maintaining asthma control.
The company said the drug was administered to patients intravenously or through subcutaneous injections every four weeks in the first study.
In the second trial, the drug was administered through subcutaneous injections.
The company said it would file for regulatory approval for the drug globally by the end of the year.
GSK's shares closed 1.5 percent lower at 1670.5 pence on Wednesday on the London Stock Exchange.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Retype Email:
Zip Code:
Privacy: We never share your email.
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved